Nurix Therapeutics 

Nurix Therapeutics 

Yahoo Finance • 5 hours ago

At a glance: stocks gapping down premarket

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Wednesday. Stock index futures edged higher before the bell Wednesday as investors dig... Full story

Yahoo Finance • 21 hours ago

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

Nurix Therapeutics, Inc. BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanof... Full story

Yahoo Finance • 13 days ago

What Nurix Therapeutics Stock's Profit Turnaround Means For Shareholders

Nurix Therapeutics reported third quarter 2026 revenue of US$673.06 million and net income of US$549.81 million, with both basic and diluted earnings per share from continuing operations turning positive compared with losses a year earlier... Full story

Yahoo Finance • 16 days ago

Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast

Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases of $25.9M of CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), $24.4M of Meta Platforms (META [https://seek... Full story

Yahoo Finance • 23 days ago

Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up

Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year. The company posted adju... Full story

Yahoo Finance • 23 days ago

Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58M

* Nurix Therapeutics press release [https://seekingalpha.com/pr/20682725-nurix-therapeutics-reports-third-quarter-2026-financial-results-and-provides-corporate-update] (NRIX [https://seekingalpha.com/symbol/NRIX]): Q3 GAAP EPS of $4.73 b... Full story

Yahoo Finance • 23 days ago

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiti... Full story

Yahoo Finance • 28 days ago

Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?

Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–b... Full story

Yahoo Finance • 30 days ago

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics, Inc. Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct... Full story

Yahoo Finance • 2 months ago

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix Therapeutics NRIX continues to make steady progress with bexobrutideg, the company's lead product candidate and primary clinical value driver. Nurix is developing bexobrutideg as an oral, brain-penetrant and highly selective Bruton's... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

Nurix Therapeutics, Inc. (NRIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impac... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in... Full story

Yahoo Finance • 3 months ago

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive appr... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics, Inc. Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor BRISBANE, Calif., Aug. 04, 2026... Full story

Yahoo Finance • 3 months ago

Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront

(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) to co-develop and co-commercialise Bexo... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics, Inc. BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted prote... Full story

Yahoo Finance • 4 months ago

Nurix Posts Wider Q2 Net Loss As Revenue Drops; Highlights $700 Mln Roche Deal

(RTTNews) - Nurix Therapeutics, Inc. (NRIX) reported financial results for the second quarter ended May 31, 2026, reflecting a wider net loss and a decline in revenue. In addition, the company provided operational and pipeline updates. Co... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical... Full story

Yahoo Finance • 4 months ago

Stocks Climb on Strength in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.55%.  September E-mini S&P futures (ESU26) are up +0.47%, and September E-mini... Full story

Yahoo Finance • 4 months ago

Stocks Weighed Down by Geopolitical Risks

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.27%.  September E-mini S&P futures (ESU26) fell -0.35%,... Full story